EDINBURGH, Scotland, Dec. 18,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that its Board of Directors has approved a special dividend to its
shareholders of 0.25 American Depositary Shares ("ADSs") for every
1 ADS held by shareholders, pending shareholder approval. The
Company intends to hold a general meeting of shareholders ("GM") at
2:00 p.m. (UK time) on Monday, December 30, 2024, at The Seafield Arms
Hotel, 17-19 Seafield St, Cullen, Buckie AB56 4SH, Scotland, United Kingdom.
The dividend is expected to be declared on December 30, 2024, and payable to shareholders
who own the Company's stock at the close of trading on January
02, 2025. Relevant details regarding the payment date for the
Company's American Depositary Shares will be announced at a later
time.
Further information regarding the proposed dividend will be
contained in the convening notice and explanatory notes for the GM,
which will be available free of charge in the Investors section of
the Company's corporate website
at https://ir.tcbiopharm.com/ and available on the SEC's
website at www.sec.gov.
"We are extremely pleased to announce this special dividend, our
shareholders have been supportive of the Company through a
difficult capital markets environment, including the Company being
the target of a nefarious and false short and distort campaign,"
said Bryan Kobel, CEO of the
Company. "We believe our shareholders deserve to be rewarded for
their steadfastness, and while we cannot force regulators to move
with alacrity or fight fraud, we believe this is a
step towards increasing value. Our commitment to returning value to
shareholders remains unwavering and we look forward to another
strong year of operational achievements in 2025."
This press release is for informational purposes only. It shall
not constitute an offer to sell or exchange nor the solicitation of
an offer to buy shares of the Company's common stock or any other
securities.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements in this Current Report on Form 6-K that do not
relate to matters of historical fact should be considered
forward-looking statements, including statements regarding the
Company's intent or ability to pay any dividends, affect any budget
savings or execute on any M&A or capital raising strategy.
These statements are based on management's current assumptions and
are neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause the
Company's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. For other important factors that could cause actual
results to differ materially from the forward-looking statements in
this Current Report on Form 6-K, please see the risks and
uncertainties identified under the heading "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 6-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid
leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-general-meeting-of-shareholders-to-approve-one-time-shareholder-dividend-302331151.html
SOURCE TC BioPharm
